EUVIMEDEUVIMED entdecken
Crossref

Discovery of ( S )- N -(2-Amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6 H )-yl)ethyl)benzamide as Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate

Daqiang Li, Zhuo Zhang, Yalei Li, Xinyi Wang, Hanyue Zhong, Huajie Yang, Yong Xi, Hongchun Liu, Aijun Shen, Youhong Hu iD

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.3c00525 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Daqiang Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Drug Research, Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 …. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China, Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A novel series of benzamide derivatives were successively designed and synthesized prepared from the pyridazinone scaffold. Among them, (S)-17b, demonstrated potent inhibitory activity in vitro toward human class I HDAC isoforms and human myelodysplastic syndrome (SKM-1) cell line. Also, (S)-17b strongly increased the intracellular level of acetyl-histone H3 and P21 simultaneously and effectively induced G1 cell cycle arrest and apoptosis. Through oral dosing in SKM-1 xenograft models, (S)-17b exhibited excellent in vivo antitumor activity. In addition, compound (S)-17b showed better antitumor efficacy on mouse models with intact immune system than those with thymus deficiencies. Furthermore, this compound displayed a favorable pharmacokinetic profile in ICR mice and SD rat, respectively, minimal metabolic property differences among hepatocytes from five species, and a low inhibition upon the human ether-a-go-go (hERG) channel with an IC50 value of 34.6 μΜ. This novel compound (S)-17b may serve as a new drug candidate for further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase InhibitorsAntineoplastic AgentsMiceHumansRatsAnimalsRats, Sprague-DawleyMice, Inbred ICRDisease Models, AnimalBenzamidesCell ProliferationCell Line, TumorDrug Screening Assays, AntitumorApoptosisStructure-Activity Relationship

Substanzen

Histone Deacetylase InhibitorsAntineoplastic AgentsBenzamides

Autor:innen und Institutionen

  • State Key Laboratory of Drug Research, Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Shanghai 201203, China.
  • School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
  • University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 110039, China.
  • Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Shanghai 201203, China.
  • Lingang Laboratory, Shanghai 200031, China.
  • School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, UCAS, Hangzhou 310024, China.

ORCID-Profile: Youhong Hu

Förderung

  • Science and Technology Commission of Shanghai Municipality
  • National Natural Science Foundation of China
  • Chinese Academy of Sciences

Zitieren

APA

Li, D., Zhang, Z., Li, Y., Wang, X., Zhong, H., Yang, H., Xi, Y., Liu, H., Shen, A., & Hu, Y. (2023). Discovery of ( S )- N -(2-Amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6 H )-yl)ethyl)benzamide as Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00525

Vancouver

Li D, Zhang Z, Li Y, Wang X, Zhong H, Yang H, et al. Discovery of ( S )- N -(2-Amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6 H )-yl)ethyl)benzamide as Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00525

BibTeX
@article{Li2023,
  author = {Li, Daqiang and Zhang, Zhuo and Li, Yalei and Wang, Xinyi and Zhong, Hanyue and Yang, Huajie and Xi, Yong and Liu, Hongchun and Shen, Aijun and Hu, Youhong},
  title = {Discovery of ( S )- N -(2-Amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6 H )-yl)ethyl)benzamide as Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.3c00525}
}
Kostenlos starten →